Investigational Device: Definition, Clinical Investigation Requirements, Application, Label and Status in ÜTS

SUMMARY
An investigational device is a device being assessed within a clinical investigation under the Tıbbi Cihaz Yönetmeliği (Medical Devices Regulation). The Regulation excludes these devices from the definitions of placing on the market, making available on the market and putting into service, and subjects them to the clinical investigation provisions of Articles 62 to 79.
In this article we set out, with verbatim quotations from the regulation and the guide, the definitions, the provision on supply to an investigator without a CE marking, the conditions for conducting a clinical investigation, the application and start process, the label wording, adverse event recording and the ÜTS and EUDAMED side.
For the ÜTS registration of your device once its clinical investigation is complete: Medical Device ÜTS Registration Consultancy
Contents
1. Investigational Device, Clinical Investigation and Sponsor: Definitions
Tıbbi Cihaz Yönetmeliği (Medical Devices Regulation), Art. 3, first paragraph:
“(c) Investigational device: a device that is being assessed within a clinical investigation,”
“(aa) Clinical investigation: any systematic investigation involving one or more volunteers, undertaken to assess the safety or performance of a device,”
“(k) Sponsor: any person, company, institution or organisation which takes responsibility for the initiation, management and financing (Amended phrase: Official Gazette 2/4/2023-32151) of the clinical investigation,”
“(ç) Investigator: the person responsible for the conduct of the clinical investigation at the investigation site,”
The sponsor is the party that initiates, manages and finances the investigation; the investigator is the person responsible at the site where it is conducted.
2. An Investigational Device Is Not Considered Placed on the Market
Three definitions in the same article expressly leave investigational devices out:
“(tt) Placing on the market: the first making available of a device, other than an investigational device, on the Turkish market,”
“(ss) Making available on the market: any supply of a device, other than an investigational device, for distribution, consumption or use on the Turkish market in the course of a commercial activity, whether in return for payment or free of charge,”
“(r) Putting into service: the stage at which a device, other than an investigational device, has been made available to the end user as being ready for use on the Turkish market for the first time for its intended purpose,”
Twelfth paragraph of Article 52, which regulates conformity assessment:
“(12) Investigational devices shall be subject to the requirements set out in Articles 62 to 79 and in the acts adopted by the Commission.”
For the concept of placing on the market, see what is placing on the market, and for conformity assessment, see conformity assessment procedure.
3. Supply to an Investigator without a CE Marking: Art. 21
Article 21, which regulates special-purpose devices:
“ARTICLE 21 - (1) The following, other than devices referred to in Article 74, which do not bear the CE marking:”
“(a) investigational devices made available to an investigator for the purpose of a clinical investigation, provided that they meet the conditions laid down in Articles 62 to 79, in Article 80, in Annex XV and in the acts adopted by the Commission,”
The paragraph ends with the words "no obstacle shall be created". In other words, an investigational device without a CE marking may be supplied to an investigator provided that it meets the clinical investigation requirements.
An investigation with a device that already bears the CE marking is regulated separately in Article 74:
“(2) Where a clinical investigation is to be conducted to assess, outside the scope of its intended purpose, a device which already bears the CE marking in accordance with the first paragraph of Article 20, Articles 62 to 79 and the acts adopted by the Commission shall apply.”
Under the first paragraph of Article 74, where a post-market clinical follow-up study that further assesses a CE-marked device within its intended purpose subjects volunteers to additional invasive or burdensome procedures, the sponsor notifies the Agency through the electronic system at least 30 days before the start of the study. For PMCF, see our article on clinical evaluation and PMCF.
4. Sponsor Outside Turkey: Legal Representative
Second paragraph of Article 62:
“(2) Where the sponsor of a clinical investigation is not established in Turkey, that sponsor shall ensure that a natural or legal person established in Turkey is designated as its legal representative. That legal representative shall be responsible for ensuring compliance with the sponsor's obligations under this Regulation and shall be the addressee for all communications with the sponsor provided for in this Regulation. Any communication to that legal representative shall be deemed to be a communication to the sponsor.”
5. Conditions for Conducting a Clinical Investigation: Art. 62
Point (c) of the third paragraph of Article 62 regulates the ethical review:
“(c) It shall be subject to scientific and ethical review. The ethical review (Additional phrase: Official Gazette 29/7/2022-31907) shall be performed by an ethics committee that has been established with the approval of the Agency in accordance with the relevant legislation and is included in the list published on the Agency's web page.”
The fourth paragraph requires all of the conditions to be met for the investigation to be conducted. Some of the conditions:
“(4) A clinical investigation as referred to in the first paragraph may be conducted only where all of the following conditions are met:”
“(a) The Agency has authorised the clinical investigation in accordance with this Regulation.”
“(b) An ethics committee, set up in accordance with the relevant legislation, has not issued a negative opinion in relation to the clinical investigation under the relevant legislation.”
“(c) The sponsor or its legal representative, pursuant to the second paragraph, is established in Turkey.”
“(ç) Appropriate protection of vulnerable populations and subjects in accordance with Articles 64 to 68.”
“(j) The requirements of Annex XV are fulfilled.”
The condition on the device itself is in point (i):
“(i) The investigational device(s) in question comply with the applicable general safety and performance requirements set out in Annex I, apart from the aspects covered by the clinical investigation”
Point (b) requires that the ethics committee has not issued a negative opinion, not that it has issued a positive one. Vulnerable populations (Articles 64 to 68) and compensation for damage to subjects (Article 69) are covered in our article on special groups and compensation for damage in clinical investigations.
6. Application and Starting the Investigation: Art. 70
“(1) The sponsor of a clinical investigation shall submit an application to the Agency accompanied by the documentation referred to in Chapter II of Annex XV. The application shall be made via the electronic system referred to in Article 73, which shall generate a single identification number for the clinical investigation to be used for all relevant communications in respect of that clinical investigation across Turkey and the EU.”
The moment of starting depends on the class of the device. Seventh paragraph:
“(a) in the case of investigational devices classified as class I or non-invasive class IIa and class IIb (Additional phrase: Official Gazette 17/8/2024-32635), unless otherwise stated in the relevant national legislation on clinical investigations of medical devices, immediately after the date of validation of the application in accordance with the fifth paragraph, and provided that an ethics committee has not issued a negative opinion in relation to the clinical investigation under the relevant legislation,”
“(b) in the case of investigational devices other than those referred to in point (a), as soon as the Agency has notified the sponsor of its authorisation of the clinical investigation, and provided that an ethics committee has not issued a negative opinion in relation to the clinical investigation under the relevant legislation,”
“the sponsor may start the clinical investigation. The Agency shall notify the sponsor of the authorisation within 45 days of the validation date referred to in the fifth paragraph. The Agency may extend this period by a further 20 days for the purpose of consulting experts.”
Under the first paragraph of Article 70, within 10 days of receiving the application the Agency notifies the sponsor whether the investigation falls within the scope of the Regulation and whether the file is complete. The fourth paragraph of Article 71 lists the cases in which authorisation is not granted, such as an application file that remains incomplete or the requirements of Article 62 not being met.
7. Label: "Exclusively for Clinical Investigation"
Point 23.2 of Annex I, particulars on the label:
“(n) an indication that the device is a medical device. If the device is intended exclusively for clinical investigation, the words ‘exclusively for clinical investigation’,”
Point 23.3, particulars on the sterile packaging:
“(e) If the device is intended exclusively for clinical investigation, the words ‘exclusively for clinical investigation’.”
For the other particulars of the label, see our article on the Turkish label and instructions for use.
8. Records, Reporting and Termination during the Investigation
First paragraph of Article 79:
“(1) The sponsor shall fully record all of the following:”
“(a) any type of adverse event that is identified in the clinical investigation plan as critical to the evaluation of the results of that clinical investigation.”
“(b) any serious adverse event.”
“(c) any device deficiency that might have led to a serious adverse event if appropriate action had not been taken, intervention had not occurred, or circumstances had been less fortunate.”
“(ç) new findings in relation to any event referred to in points (a) to (c).”
For devices made available on the market, serious incident reporting runs from Article 85, which excludes investigational devices. Under the fifth paragraph of Article 79, the vigilance provisions of Articles 85 to 88 apply to the PMCF studies in the first paragraph of Article 74. For vigilance, see vigilance and serious incident reporting.
Sixth paragraph of Article 72:
“(6) The sponsor shall establish a procedure for emergency situations which enables the immediate identification and, where necessary, an immediate recall of the devices used in the investigation.”
Under the fifth paragraph of Article 77, the sponsor submits the clinical investigation report to the Agency within one year of the end of the investigation, or within three months of early termination or temporary halt. Under the sixth paragraph, the report and its summary become publicly available at the latest when the device is registered pursuant to Article 29 and before it is placed on the market.
9. Investigational Devices in ÜTS and EUDAMED
The TİTCK ÜTS Kayıt Kılavuzu (ÜTS Registration Guide, TCKKD-KLVZ-03) has no separate document type or product registration field for an investigational device. Investigational devices appear in the Guide's conformity assessment articles as an exception. Art. 61:
“(4) Manufacturers of class I devices, other than ITC (custom-made devices) or investigational devices,”
The same exception is repeated in the paragraphs on class IIa, IIb and III. When the investigation is complete and the device is to be placed on the market, the document and product are registered in ÜTS; the steps are in our pages on ÜTS document registration and ÜTS medical device product registration respectively.
One item of information entered in the device registration on the EUDAMED side is in Part A of Annex VI:
“2.11. Where applicable, the single identification number for the clinical investigation or investigations conducted with respect to the device, or a link to the clinical investigation registration in the electronic system on clinical investigations,”
The EUDAMED Q&A text published in Turkish by the TİTCK:
“In order to use the CI/PS module, e.g. to submit a clinical investigation or performance study application or to report a serious adverse event, sponsors of clinical investigations/performance studies must register as an actor in the ACT module and obtain an Actor ID.”
“The CI/PS module is not available for voluntary use; it will be made available when it becomes mandatory, and its use will be mandatory from that point on”
For the EUDAMED modules, see our page on what is EUDAMED.
10. Frequently Asked Questions
Is an investigational device registered in ÜTS?
The TCKKD-KLVZ-03 guide has no separate document type or product registration field for an investigational device. Under the Regulation, these devices are not considered placed on the market and are subject to Articles 62 to 79.
Does an investigational device bear the CE marking?
Under Article 21, no obstacle is created to supplying an investigational device without a CE marking to an investigator, provided that it meets the clinical investigation requirements. The device must nevertheless comply with the applicable requirements of Annex I under point (i) of the fourth paragraph of Article 62.
Is a positive opinion from the ethics committee required?
Point (b) of the fourth paragraph of Article 62 requires that the ethics committee has not issued a negative opinion.
For a class I investigational device, is the Agency's authorisation awaited?
Under the seventh paragraph of Article 70, for class I and non-invasive class IIa and IIb devices, unless the national legislation provides otherwise, the investigation may start after the validation date of the application and provided that the ethics committee has not issued a negative opinion. For other devices, the Agency's notification of authorisation is awaited.
Which wording appears on the label?
Under points 23.2 and 23.3 of Annex I, if the device is intended exclusively for clinical investigation, the words "exclusively for clinical investigation" appear on the label and on the sterile packaging.
For the ÜTS registration of your device once its clinical investigation is complete: Medical Device ÜTS Registration Consultancy
Sources



